Interactions between oral contraceptive status and GSTM1 and GSTT1 deletions on insulin-like growth factor-1 (IGF-1) plasma levels in young healthy women

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 432-437

  Henningson, M C K ^a   Hietala, M ^a   Bageman E ^a   Olsson, H ^a   Jernstrom H ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Gene mutations; GSTM1; GSTP1; GSTT1; IGF 1; Metabolism; Oral contraception

Indexed keywords

CONTRACEPTIVE AGENT; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; BODY SIZE; BODY WEIGHT; BREAST CANCER; BREAST DEVELOPMENT; CANCER RISK; CONTROLLED STUDY; DRUG USE; ENZYME ACTIVITY; FEMALE; GENE DELETION; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HEALTH STATUS; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL CONTRACEPTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RADIOIMMUNOASSAY; WOMEN'S HEALTH;

ADULT; ALGORITHMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HEALTH; HUMANS; INSULIN-LIKE GROWTH FACTOR I; QUESTIONNAIRES; YOUNG ADULT;

EID: 78649629450     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.10.003     Document Type: Article

References (40)

1. Stewart C.E., Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol. Rev. 1996, 76:1005-1026.
2. Dickson R.B., Russo J. Biochemical Control of Breast Development 2000, Williams and Wilkins, Philadelphia. 2nd ed.
3. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
4. Schernhammer E.S., Holly J.M., Hunter D.J., Pollak M.N., Hankinson S.E. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 2006, 13:583-592.
5. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
6. Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010, 11:530-542.
7. Caufriez A., Copinschi G. Somatomedins and steroids. Horm. Res. 1986, 24:185-188.
8. Jernström H., Olsson H. Suppression of plasma insulin-like growth factor-1 levels in healthy, nulliparous, young women using low dose oral contraceptives. Gynecol Obstet Invest. 1994, 38:261-265.
9. Jernström H., Deal C., Wilkin F., et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomark. Prev. 2001, 10:377-384.
10. Jernström H., Sandberg T., Bågeman E., Borg Å., Olsson H. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br. J. Cancer 2005, 92:857-866.
11. Jernström H., Chu W., Vesprini D., et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol. Genet. Metab. 2001, 72:144-154.
12. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomark. Prev. 1997, 6:733-743.
13. Garte S., Gaspari L., Alexandrie A.K., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomark. Prev. 2001, 10:1239-1248.
14. Fuciarelli M., Caccuri A., De Francesca M., Ferazzoli F., Piacentini S., Porreca F. Modulation of the GSTT1 activity by the GSTM1 phenotype in a sample of Italian farm-workers. Arch. Toxicol. 2009, 83:115-120.
15. Kelley M.K., Engqvist-Goldstein A., Montali J.A., Wheatley J.B., Schmidt D.E., Kauvar L.M. Variability of glutathione S-transferase isoenzyme patterns in matched normal and cancer human breast tissue. Biochem. J. 1994, 304(Pt 3):843-848.
16. Sundberg K., Johansson A.S., Stenberg G., et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998, 19:433-436.
17. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 1999, 8:843-854.
18. Mitrunen K., Jourenkova N., Kataja V., et al. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol. Biomark. Prev. 2001, 10:229-236.
19. Reding K.W., Weiss N.S., Chen C., et al. Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2009, 18:1461-1467.
20. Millikan R., Pittman G., Tse C.K., Savitz D.A., Newman B., Bell D. Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol. Biomark. Prev. 2000, 9:567-573.
21. Matheson M.C., Stevenson T., Akbarzadeh S., Propert D.N. GSTT1 null genotype increases risk of premenopausal breast cancer. Cancer Lett. 2002, 181:73-79.
22. Torresan C., Oliveira M.M., Torrezan G.T., et al. Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin. Exp. Med. 2008, 8:65-71.
23. Vogl F.D., Taioli E., Maugard C., et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol. Biomark. Prev. 2004, 13:1473-1479.
24. Helzlsouer K.J., Selmin O., Huang H.Y., et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J. Natl Cancer Inst. 1998, 90:512-518.
25. Steck S.E., Gaudet M.M., Britton J.A., et al. Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis 2007, 28:1954-1959.
26. Li C.I., Malone K.E., White E., Daling J.R. Age when maximum height is reached as a risk factor for breast cancer among young U.S. women. Epidemiology 1997, 8:559-565.
27. Henningson M., Bageman E., Sandberg T., Borg A., Olsson H., Jernstrom H. Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Fam Cancer. 2007, 6:445-452.
28. Bang P., Eriksson U., Sara V., Wivall I.L., Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol Copenh 1991, 124:620-629.
29. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996, 347:1713-1727. Collaborative Group on Hormonal Factors in Breast Cancer.
30. Jernström H., Loman N., Johannsson O.T., Borg Å., Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur. J. Cancer 2005, 41:2312-2320.
31. Hannaford P.C., Selvaraj S., Elliott A.M., Angus V., Iversen L., Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007, 335:651.
32. Colditz G.A., Frazier A.L. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol. Biomark. Prev. 1995, 4:567-571.
33. Juul A., Main K., Blum W.F., Lindholm J., Ranke M.B., Skakkebaek N.E. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol Oxf 1994, 41:85-93.
34. Ruder E.H., Dorgan J.F., Kranz S., Kris-Etherton P.M., Hartman T.J. Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin. Breast Cancer 2008, 8:334-342.
35. Li C.I., Stanford J.L., Daling J.R. Anthropometric variables in relation to risk of breast cancer in middle-aged women. Int. J. Epidemiol. 2000, 29:208-213.
36. Ballard-Barbash R. Anthropometry and breast cancer. Body size--a moving target. Cancer 1994, 74:1090-1100.
37. Friedenreich C.M. Review of anthropometric factors and breast cancer risk. Eur. J. Cancer Prev. 2001, 10:15-32.
38. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343:692-695.
39. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1995, 56:265-271.
40. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998, 62:676-689.